Cardiovascular disease after hodgkin lymphoma treatment 40-year disease risk

JAMA Internal Medicine

Volumn 175, Issue 6, 2015, Pages 1007-1017

  Van Nimwegen, Frederika A ^a   Schaapveld, Michael ^b   Janus, Cécile P M ^c   Krol, Augustinus D G ^d   Petersen, Eefke J ^e   Raemaekers, John M M ^f   Kok, Wouter E M ^g   Aleman, Berthe M P ^a   Van Leeuwen, Flora E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Integraal Kankercentrum Amsterdam   (Netherlands)

^c ERASMUS MC CANCER INSTITUTE   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE SULFATE; VINCRISTINE; VINCRISTINE SULFATE;

ADOLESCENT; ADULT; ARTICLE; ASSESSMENT OF HUMANS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILD; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HODGKIN DISEASE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; STANDARDIZED INCIDENCE RATIO; TERMINOLOGY CRITERIA FOR ADVERSE EVENT VERSION 4; VALVULAR HEART DISEASE; YOUNG ADULT; ADVERSE EFFECTS; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; INCIDENCE; MULTICENTER STUDY; NETHERLANDS; PRESCHOOL CHILD; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; INCIDENCE; MALE; NETHERLANDS; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 84930751655     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.1180     Document Type: Article

References (44)

1. Integraal Kankercentrum Nederland. Dutch Cancer figures, 2012. http://www.cijfersoverkanker.nl. Accessed February 20, 2013.
2. Aleman BMP, van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol. 2003;21(18):3431-3439.
3. Möller TR, Garwicz S, Barlow L, et al Association of the Nordic Cancer Registries; Nordic Society for Pediatric Hematology and Oncology. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol. 2001;19(13):3173-3181.
4. van Leeuwen FE, Klokman WJ, Veer MB, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol. 2000;18(3):487-497.
5. Travis LB, Ng AK, Allan JM, et al. Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst. 2012;104(5):357-370.
6. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol. 2011;154(1):23-31.
7. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290(21):2831-2837.
8. Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood. 2011;117(2):412-418.
9. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. J Clin Oncol. 1993;11(7):1208-1215.
10. Ng AK, Bernardo MP, Weller E, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.JClin Oncol. 2002;20(8):2101-2108.
11. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma. 2008;49(8):1486-1493.
12. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst. 2007;99(3):206-214.
13. Aleman BMP, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood. 2007;109(5):1878-1886.
14. De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood. 2009;113(16):3679-3681.
15. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin's disease: a 20-year follow-up study. J Clin Oncol. 1994;12(2):312-325.
16. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0. Bethesda, MD: National Cancer Institute, National Institutes of Health; 2009.
17. Feijen EL, van der Pal HJ, van Dalen EC, et al. A new method to facilitate valid and consistent grading cardiac events in childhood cancer survivors using medical records. PLoS One.2014;9(7):e100432.
18. Carde P, Burgers JM, Henry-Amar M, et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol. 1988;6(2):239-252.
19. Eghbali H, Raemaekers J, Carde P; EORTC Lymphoma Group. The EORTC strategy in the treatment of Hodgkin's lymphoma. Eur J Haematol Suppl. 2005;75(suppl66):135-140.
20. Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al European Organisation for Research and Treatment of Cancer. The achievements of the EORTC Lymphoma Group. Eur J Cancer. 2002;38(suppl 4):S107-S113.
21. Somers R, Tubiana M, Henry-Amar M. EORTC Lymphoma Cooperative Group studies in clinical stage I-II Hodgkin's disease 1963-1987. Recent Results Cancer Res. 1989;117:175-181.
22. Tubiana M, Henry-Amar M, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease: the EORTC Lymphoma Group controlled clinical trials: 1964-1987. Blood. 1989;73(1):47-56.
23. van Eggermond AM, Schaapveld M, Lugtenburg PJ, et al. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma.Blood. 2014;124(3):319-327.
24. van den Belt-Dusebout AW, Nuver J, de Wit R, et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol. 2006;24(3):467-475.
25. Gijsen R, Poos MJJC. Coronaire Hartziekten: Omvang van het Probleem: Achtergronden en Details bij Cijfers uit Huisartsenregistraties. 2005. http://www.rivm.nl/Onderwerpen/V/Volksgezondheid-Toekomst-Verkenning-VTV. Accessed February 15, 2005.
26. Netherlands Institute for Health Services Research. NIVEL primary care database. 2014. http://www.nivel.nl/en/dossier/nivel-primary-care-database. Accessed February 25, 2014.
27. Breslow NE, Day NE. The Design and Analysis of Cohort Studies. Vol II. Lyon, France: International Agency for Research on Cancer; 1987:1-406. Statistical methods in cancer research.
28. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
29. Mulrooney DA, Yeazel MW, Kawashima T, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ. 2009;339:b4606.
30. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med. 1996;125(1):47-58.
31. Kremer LC, van Dalen EC, Offringa M, Ottenkamp J, VoÛte PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001;19(1):191-196.
32. Oki T, Fukuda N, Iuchi A, et al. Possible mechanisms of mitral regurgitation in dilated hearts: a study using transesophageal echocardiography. Clin Cardiol. 1996;19(8):639-643.
33. Allen J, Thomson JD, Lewis IJ, Gibbs JL. Mitral regurgitation after anthracycline treatment for childhood malignancy. Heart. 2001;85(4):430-432.
34. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 2010;28(8):1308-1315.
35. Moser EC, Noordijk EM, van Leeuwen FE, et al. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood. 2006;107(7):2912-2919.
36. McGale P, Darby SC, Hall P, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden.Radiother Oncol. 2011;100(2):167-175.
37. Bowles EJA, Wellman R, Feigelson HS, et al Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst. 2012;104(17):1293-1305.
38. Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma.Ann Oncol. 2013;24(8):2113-2118.
39. Maraldo MV, Brodin NP, Vogelius IR, et al. Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012;83(4):1232-1237.
40. Sieswerda E, Postma A, van Dalen EC, et al Late Effects of Childhood Cancer Task Force of the Dutch Childhood Oncology Group (DCOG LATER). The Dutch Childhood Oncology Group guideline for follow-up of asymptomatic cardiac dysfunction in childhood cancer survivors. Ann Oncol. 2012;23(8):2191-2198.
41. Children's Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 3.0. Arcadia, CA: Children's Oncology Group; 2008.
42. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group long-term follow-up guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004;22(24):4979-4990.
43. Raemaekers JM, André MP, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol. 2014;32(12):1188-1194.
44. Specht L, Yahalom J, Illidge T, et al ILROG. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854-862.